AI assistant
Sending…
Kezar Life Sciences, Inc. — Director's Dealing 2018
Jun 20, 2018
34845_dirs_2018-06-20_2810397f-fb08-4c42-967d-51f05427cce7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Kezar Life Sciences, Inc. (KZR)
CIK: 0001645666
Period of Report: 2018-06-20
Reporting Person: Aberdare Management Company, LLC (10% Owner)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series A Convertible Preferred Stock | $ | Common Stock (105162) | Direct | ||
| Series B Convertible Preferred Stock | $ | Common Stock (31481) | Direct |
Footnotes
F1: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock is convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, has no expiration date and will convert into shares of Common Stock upon the closing of the Issuer's initial public offering.
F2: The members of Aberdare Management Company, LLC are Paul H. Klingenstein and Kathleen R. Bole.
More from Kezar Life Sciences, Inc.
Delisting Announcement
2026
May 11
M&A Activity
2026
May 11
Interim / Quarterly Report
2026
May 11
Annual Report
2026
Apr 30
Legal Proceedings Report
2026
Apr 3
Merger & Acquisition
2026
Mar 30
M&A Activity
2026
Mar 30
Major Shareholding Notification
2026
Feb 9
Major Shareholding Notification
2025
Nov 14
Interim / Quarterly Report
2025
Nov 12